Business Context and Reporting Period
This Form 8-K was filed by Histogenics Corporation (not Ocugen, Inc.) on September 16, 2016, reporting events occurring on September 15, 2016. The filing details the entry into a Material Definitive Agreement for a private placement of securities.
Key Financial Metrics and Transaction Details
- Total Capital Raised: $30 million.
- Common Stock Issued: 2,653,553 shares at $2.25 per share.
- Series A Convertible Preferred Stock: 24,158.8688 shares (stated value $1,000/share), convertible into approximately 10,679,781 common shares.
- Warrants Issued: Warrants to purchase up to 13,333,334 common shares at an exercise price of $2.25 per share.
- Use of Proceeds: Working capital and general corporate purposes.
- Placement Agent: H.C. Wainwright & Co., LLC (received a warrant for 133,333 shares).
Material Changes and Insider Participation
Affiliates of certain Board of Directors participated in the private placement, purchasing an aggregate of 283,045 shares of common stock, 2,563.1451 shares of Series A Preferred Stock, and receiving warrants for up to 1,422,221 shares. The transaction is subject to customary closing conditions and stockholder approval for the conversion feature of the preferred stock.
Outlook, Risks, and Contingencies
- Stockholder Approval: The conversion of Series A Preferred Stock and the exercisability of warrants are contingent upon stockholder approval.
- NASDAQ Compliance: Issuance is structured to ensure that shares issued at closing plus convertible shares do not exceed 20% of outstanding common stock.
- Beneficial Ownership Limits: Holders cannot convert if it results in beneficial ownership exceeding 4.99% (adjustable to 9.99% with notice).
- Registration: The company agreed to file registration statements for the resale of securities; the offering relies on Rule 506 exemptions.
Investor Verification Checklist
- Verify the final closing date and confirmation of stockholder approval for the conversion feature.
- Confirm the exact dilution impact on existing shareholders post-conversion of preferred stock and warrant exercise.
- Review the filed Certificate of Designation (Exhibit 3.3) for specific liquidation preferences and voting rights.
- Monitor the filing of the Form D and the registration statement for resale of the securities.